Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Webcasts|April 26, 2024
How Pharmaceutical Companies Can Best Optimize Enterprise Asset Management, Maintenance Operations, and Master Data to Achieve Success
Author(s)Prometheus Group
Webinar Date/Time: Wed, May 22, 2024 11:00 AM EDT
Pharmaceutical companies must reduce unplanned downtime through best practices in planning and scheduling, master data, and operational safety to remain competitive and ensure drug quality. If a pharmaceutical company’s maintenance is reactive rather than proactive, production may be interrupted for a multitude of maintenance reasons, leading to costly batch reprocessing.
Register Free:
Event Overview:
Downtime from equipment and asset failures disrupts pharmaceutical production and bottom-line revenue. Reactive maintenance increases the risk of issues, such as contamination, compromising quality and reputation.
Pharmaceutical companies must reduce unplanned downtime through best practices in planning and scheduling, master data, and operational safety to remain competitive and ensure drug quality. If a pharmaceutical company’s maintenance is reactive rather than proactive, production may be interrupted for a multitude of maintenance reasons, leading to costly batch reprocessing.
Find out how world-class standards in maintenance, planning, scheduling, operations, safety, and master data can improve equipment and asset uptime and availability. Learn how best practices in routine maintenance, operations and safety, and master data can help pharmaceutical companies gain a competitive edge while providing consumers with high-quality products.
Key Learning Objectives:
- Understand digital transformation and what it means for enterprise asset management.
- Identify common pitfalls in planning and scheduling processes and learn how to mitigate them.
- Optimize the availability of spare parts inventory with a just-in-time inventory approach.
- Recognize the reasons master data is imperative.
- Justify and build a compelling business case for maintenance planning and scheduling with hard-dollar and soft-dollar savings.
Who Should Attend:
- Asset Engineer
- Asset Reliability and Maintenance Manager/Director
- Business Process Owner
- Corporate Data Management
- Corporate Strategic Planner
- Computerized Maintenance Management System (CMMS) Engineer
- Digital Transformation Leader
- Digital Solutions and Applications Leader
- Engineering and Maintenance Manager
- Enterprise Asset Management (EAM) Leader
- Enterprise Resource Planning (ERP) Leader
- Equipment Reliability Program Manager
- IBM Maximo Application Leader
- Master Data Leader
- Maintenance Planner and Scheduler
- Maintenance Engineer/Supervisor/Manager/Director
- Maintenance and Reliability Manager/Director
- Operations Director
- Oracle Application Leader
- Planning and Scheduling Manager/Supervisor
- Reliability Engineer
- Regional Asset Planner
- SAP Application Leader
- Work Management Planner
Speaker:
Karen Sofia Gutierrez
Functional Consultant
Prometheus Group
Karen Sofia Gutierrez is a Functional Consultant at Prometheus Group. She has international experience in quality, production engineering, and project management, with a bachelor’s in industrial production technologies and a background in software, engineering, manufacturing. She is dedicated to optimizing processes and delivering exceptional results by combining her technical expertise with a customer-centric mindset. At Prometheus Group, she speaks with clients in many industries on enterprise asset management best practices and how they can implement them in their organizations.
Register Free:
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.